Correction to: Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017 by Greenwood, John et al.
Greenwood et al. Fluids Barriers CNS  (2018) 15:3 
https://doi.org/10.1186/s12987-017-0086-x
CORRECTION
Correction to: Current research into brain 
barriers and the delivery of therapeutics 
for neurological diseases: a report on CNS 
barrier congress London, UK, 2017
John Greenwood1, Margareta Hammarlund‑Udenaes2, Hazel C. Jones3*, Alan W. Stitt4, 
Roosmarijn E. Vandenbroucke5,6, Ignacio A. Romero7, Matthew Campbell8, Gert Fricker9, Birger Brodin10, 
Heiko Manninga11, Pieter J. Gaillard12, Markus Schwaninger13, Carl Webster14, Krzysztof B. Wicher15 
and Michel Khrestchatisky16,17
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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After publication of the article [1], it has been brought to 
our attention that there are some errors in the formatting 
of names in the final version of the article.
Firstly, the article’s fifth author had their name spelt 
incorrectly. Previously included as “Roosmarijn E. Van-
denbrouke”, the correct spelling is “Roosmarijn E. Van-
denbroucke”. This error was present in the author list and 
page 3 of the article.
Furthermore, author names in the article references 
had formatting issues. This occurred in cases where “van” 
is part of the naming structure. In these cases the rest of 
the last name was included incorrectly as an initial. The 
references affected are listed below with their corrected 
author list.
Reference #7 should read: Vandenbroucke RE, Dejon-
ckheere E, Van Lint P, Demeestere D, Van Wonterghem 
E, Vanlaere I, et al.
Reference #8 should read: Brkic M, Balusu S, Van 
Wonterghem E, Gorlé N, Benilova I, Kremer A, et al.
Reference #9 should read: Balusu S, Van Wonterghem 
E, De Rycke R, Raemdonck K, Stremersch S, Gevaert 
K, et al.
Reference #10 should read: Reijerkerk A, Lopez-Ram-
irez MA, van Het Hof B, Drexhage JA, Kamphuis WW, 
Kooij G, et al.
Reference #22 should read: Loryan I, Sinha V, Mackie 
C, Van Peer A, Drinkenburg W, Vermeulen A, et al.
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